抑真菌剂相关的专利数据

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
141	P2y1 receptor inhibitor derived from fungus	JP2008201353	2008-08-05	JP2010037260A	2010-02-18	OZAKI YUKIO; SATO KANEO; AKAHA KATSUYUKI
<P>PROBLEM TO BE SOLVED: To provide a P2Y1 receptor inhibitor usable as a supplement for thrombosis prevention and an antithrombotic agent for the treatment of thrombosis by finding a substance having an effect to specifically inhibit an ADP receptor, especially P2Y1 receptor, from an extraction component of the fruit body and mycelium of a certain kind of fungi. <P>SOLUTION: The P2Y1 receptor inhibitor derived from fungus contains, as an active component, the fruit body and mycelium or extract of the fruit body and mycelium of one or more kinds of fungi selected from Fistulina hepatica, Lentinus edodes, Sparassis crispa, Agaricus blazei, Hericium erinaceus, Cordyceps sinensis and Gonoderma amboinense. <P>COPYRIGHT: (C)2010,JPO&INPIT
142	Oral dosage form including antiplatelet agent and acid inhibitor	JP2013172493	2013-08-22	JP2013256525A	2013-12-26	GOLDSMITH MARK A; VADAS ELIZABETH
PROBLEM TO BE SOLVED: To provide co-administering an antiplatelet agent and an acid inhibitor, and oral dosage forms containing a combination of an antiplatelet agent and an acid inhibitor, for preventing or ameliorating the gastrointestinal disorders associated with antiplatelet agents.SOLUTION: Oral dosage comprises an adenosine diphosphate antagonist in combination with an acid inhibitor, and may comprise a variety of acid inhibitors including, but not limited to, proton pump inhibitors, H2 blockers, and alkalizing agents. In some embodiments, the oral dosage form and/or active form is at least partially enteric-coated.
143	사상균 방지제를 이용한 폐수처리 방법	KR1020020083794	2002-12-26	KR1020040057192A	2004-07-02	김해룡; 오요환; 곽영세
PURPOSE: A wastewater treatment method by using filamentous fungus inhibitor is provided to prevent sludge bulking and reduce COD (chemical oxygen demand) and suspended solid by using activated slag as the filamentous fungus inhibitor in the sludge activation process, thereby effectively inhibiting filamentous fungi. CONSTITUTION: The wastewater treatment method in the sludge activation process comprises the step of directly injecting 100 to 150 parts per million of activated slag powder into an aeration tank for 3 to 5 days when the total amount of suspended solid in the aeration tank has MLSS (mixed liquor suspended solid) concentration of 2000 to 3000 parts per million, wherein the activated slag powder is prepared by milling the heat treated slag to a particle size corresponding to a sieve size of 100 to 200 mesh after heat treating slag to a high temperature of 600 to 800 deg.C, and wherein the activated slag powder is injected into an end of the aeration tank.
144	Immune-suppressing agent for transplantation and antiallergy agent	JP25647684	1984-12-06	JPS61134312A	1986-06-21	UMEZAWA HAMAO; TAKEUCHI TOMIO; ISHIZUKA MASAAKI; ABE FUMINORI; FUJII AKIO; NAKAMURA TERUYA
PURPOSE: To provide an agent for suppressing the immunity in transplantation of organs, containing spergualin or its salt as an active component, free from side effects, and effective to suppress the transplantation immune reaction such as the rejection in the transplantation of organs such as kidney, heart, endocrine organs, skin, etc. CONSTITUTION: The objective agent contains spergualin or its pharmacologically permissible salt as an active component. The compound can be used as it is, however, it is administered usually together with a vehicle or carrier in the form of a drug preparation. For an injection, it is used by mixing with a liquid carrier, preferably physiological saline water, various buffer solutions, an aqueous solution of a sugar such as mannitol or cyclitols such as sugar alcohol, inositol, etc., or glycol such as ethylene glycol. The content of the active component is preferably 1W10wt% for injection, and 5W100wt%, preferably 25W100wt% for capsule, granule or powder. COPYRIGHT: (C)1986,JPO&Japio
145	내부기생충 및 외부기생충 구제제	KR1019997005264	1997-12-11	KR1020000057545A	2000-09-25	시리니안키르코; 도른후베르트; 히셴케르스틴; 호이캄프울리히; 쿠야네크리하르트
PURPOSE: An endoparasiticidal and ectoparasiticidal agent is provided to exterminate both endoparasits and ectoparasites in one way administration, which is different from conventional endoparasticidal agent for oral or non-oral administration and ectoparasiticidal agent for transdermal administration. CONSTITUTION: Endoparasiticidal and ectoparasiticidal agents comprise at least one avermectin, 22,23-dihydroavermectin B1 (ivermectin) or milbemycin from the class of macrocyclic lactones with agonists or antagonists of nicotinergenic acetylcholine receptors of insects, optionally in the presence of other active substances such as diluents or carriers.
146	프로테아제 저해자 및 그 변이체의 사상균 내에서의 발현	KR1020127020686	2004-10-22	KR1020120099303A	2012-09-07	데노벨한스; 에스텔데이비드에이; 류웨이; 파워스코트디; 슈미트브라이언; 왕후아밍
본원에서 기술한 것은 프로테아제 저해자, 그 변이체 및 그들의 생산방법이다.
147	프로테아제 저해자 및 그 변이체의 사상균 내에서의 발현	KR1020117024313	2004-10-22	KR101348530B1	2014-02-14	데노벨한스; 에스텔데이비드에이; 류웨이; 파워스코트디; 슈미트브라이언; 왕후아밍
본원에서 기술한 것은 프로테아제 저해자, 그 변이체 및 그들의 생산방법이다.
148	Antiarrhythmic drug and atrial fibrillation inhibitor	JP2012018977	2012-01-31	JP2012236814A	2012-12-06	SUGIYAMA ATSUSHI
PROBLEM TO BE SOLVED: To provide an antiarrhythmic drug and an atrial fibrillation inhibitor having an excellent inhibitory action relative to arrhythmia including atrial fibrillation, less side effects and high stability, a sustained atrial fibrillation model suitably used for screening of the atrial fibrillation and a method for producing the same, and a method for screening the atrial fibrillation inhibitor.SOLUTION: An atrial fibrillation inhibitor comprises a compound represented by any of formula (I) to (VI) or a pharmacologically acceptable salt thereof. In formula (III), Gluc represents glucuronic acid.
149	抗血小板薬及び酸阻害薬を含む経口剤形	JP2015195643	2015-10-01	JP2016028098A	2016-02-25	マルクエー.ゴルドスミトフ; エリザベトフバダス
【課題】血小板凝集を抑制し、凝血カスケードが活性化されるプロトロンビン及びトロンビン状態から生じる疾患を治療し、心臓血管疾患のリスクを低下させ、且つ抗血小板薬に伴う胃腸障害を軽減するための経口剤形の提供。【解決手段】抗血小板薬である第1の活性成分の治療有効量と、酸阻害薬である第2の活性成分の治療有効量とを含むカプセル及び錠剤等の経口剤形であり、該抗血小板薬がクロピドグレル等のアデノシン二リン酸アンタゴニストであり、酸阻害薬がプラスグレル等のプロトンポンプ阻害薬である、該経口剤形。【選択図】なし
150	FUNGAL PEPC INHIBITOR	PCT/EP2008/066605	2008-12-02	WO2009071530A1	2009-06-11	LEHMBECK, Jan; UDAGAWA, Hiroaki
The present invention relates to an isolated polypeptide having PepC inhibitory activityas well as to a methodfor producing a heterologous polypeptide of interest in an Aspergillus host cell comprising: (a) cultivating the Aspergillushost cell comprising a first and a second nucleic acid sequences under conditions conducive for the expression of the polypeptides encoded by the said first and second nucleic acid sequences, and wherein the first nucleic acid sequence encodes a heterologous polypeptide of interest and the second nucleic acid encodes the inhibitor polypeptide of the invention, and wherein the inhibitor polypeptide is expressed from a recombinant nucleic acid construct resulting in an increased level of the inhibitor polypeptide compared to an Aspergillushost cell not comprising the recombinant nucleic acid construct; and (b) recovering the heterologous polypeptide.
151	프로테아제 저해자 및 그 변이체의 사상균 내에서의 발현	KR1020117024313	2004-10-22	KR1020110119844A	2011-11-02	데노벨한스; 에스텔데이비드에이; 류웨이; 파워스코트디; 슈미트브라이언; 왕후아밍
본원에서 기술한 것은 프로테아제 저해자, 그 변이체 및 그들의 생산방법이다.
152	프로테아제 저해자 및 그 변이체의 사상균 내에서의 발현	KR1020067007200	2004-10-22	KR1020060111451A	2006-10-27	데노벨한스; 에스텔데이비드에이; 류웨이; 파워스코트디; 슈미트브라이언; 왕후아밍
Described herein are protease inhibitors, variants thereof and methods for their production.
153	VIRAL AND FUNGAL INHIBITORS	EP09818273.6	2009-09-23	EP2344481B9	2014-12-31	PADMANABHAN, Radhakrishnan; GROUTAS, William C.; KORBA, Brent E.

154	중심체 DNA를 이용한 항진균제의 탐색 방법 및 이를 이용하여 분리한 항진균제	KR1020030051104	2003-07-24	KR1020050012020A	2005-01-31	윤혜주; 신승구
PURPOSE: A screening method of an antifungal agent and the isolated antifungal agent using the same are provided, thereby easily screening the antifungal agent which inhibits chromosome separation in fungi to inhibit their cell division. CONSTITUTION: The screening method of an antifungal agent comprises the steps of: providing a transformed host cell containing centrosome DNA of Saccharomyces cerevisiae or DNA having a 90% homology to the same centrosome DNA, a hybrid promoter with a galactose-inducible promoter, and a lacZ reporter gene; contacting a test compound with the transformed host cell; and determining whether the transcription of the reporter gene is inhibited, wherein the host cell is Saccharomyces cerevisiae(KCTC 10481BP) or Candida glabrata.
155	Screen for inhibitors of fungal IPC synthase	US833814	1997-04-09	US5976866A	1999-11-02	Steven Alan Heidler; Jeffrey Alan Radding; Debra Ann Young
This invention provides novel fungal strains altered in IPC synthase production, and a method for screening for inhibitors of fungal IPC synthase using whole cells.
156	作爲殺真菌劑之金屬酶抑制劑化合物（二）	TW104111921	2015-04-14	TW201623252A	2016-07-01	洛索麥可R; LOSO, MICHAEL R.; 蓋斯塔佛森葛瑞D; GUSTAFSON, GARY D.; 久保田朝子; KUBOTA, ASAKO; 葉普毛里斯C; YAP, MAURICE C.; 布宣恩札克里A; BUCHAN, ZACHARY A.; 史戴華金伯利M; STEWARD, KIMBERLY M.; 蕭倫伯格麥可T; SULLENBERGER, MICHAEL T.; 虎克斯特拉威廉J; HOEKSTRA, WILLIAM J.; 葉茲克里斯托福M; YATES, CHRISTOPHER M.
本發明描述具有金屬酶調節活性之具化學式I之化合物，及治療藉由此等金屬酶調節之其疾病、異常或症狀之方法。
157	作爲殺真菌劑之金屬酶抑制劑化合物（一）	TW104111924	2015-04-14	TW201542090A	2015-11-16	洛索麥可R; LOSO, MICHAEL R.; 蓋斯塔佛森葛瑞D; GUSTAFSON, GARY D.; 久保田朝子; KUBOTA, ASAKO; 葉普毛里斯C; YAP, MAURICE C.; 布宣恩札克里A; BUCHAN, ZACHARY A.; 史戴華金伯利M; STEWARD, KIMBERLY M.; 蕭倫伯格麥可T; SULLENBERGER, MICHAEL T.; 虎克斯特拉威廉J; HOEKSTRA, WILLIAM J.; 葉茲克里斯托福M; YATES, CHRISTOPHER M.
本發明描述具有金屬酶調節活性之具化學式I之化合物，及治療藉由此等金屬酶調節之其疾病、異常或症狀之方法。
158	Hyaluronidase activity inhibitor, antibacterial agent against helicobacter pylori, and bamboo extract composition	JP2006346375	2006-12-22	JP2008156270A	2008-07-10	MIYAZAKI AIKO; YOSHINO AKIRA; TAKESHITA KEI
<P>PROBLEM TO BE SOLVED: To provide a hyaluronidase activity inhibitor containing as a component a safe and easily ingestable bamboo extract composition using the skin of Phyllostachys pubescens of a natural product as a raw material, to provide an antibacterial agent against Helicobacter pylori, and to provide a safe and easily ingestable bamboo extract composition using the skin of the Phyllostachys pubescens of the natural product. <P>SOLUTION: The hyaluronidase activity inhibitor contains the bamboo extract composition obtained by adding an organic solvent or the organic solvent and water to a treated material obtained by treating the bamboo skin by a hydrolysis method to carry out the extraction as an active ingredient. The inhibitor can inhibit the development of allergy affected by the hyaluronidase activity and gastritis or the like caused by the Helicobacter pylori, because the bamboo extract composition has the hyaluronidase activity-inhibiting activity and the germicidal activity effective to the Helicobacter pylori. <P>COPYRIGHT: (C)2008,JPO&INPIT
159	IMMUNOPOTENTIATOR OR ANTIALLERGIC AGENT	PCT/JP2009/066203	2009-09-10	WO2010035675A1	2010-04-01	UEDA, Fumitaka; KAKINUMA, Chihaya; SERIZAWA, Yuriko
An immunopotentiator or antiallergic agent includes: a pulverized product or extract of a plant belonging to the genus Salacia.
160	Use of ketol-acid reductoisomerase inhibitor for treatment of fungal disease affecting crop	JP2010270135	2010-12-03	JP2011093909A	2011-05-12	DUMAS RENAUD; LEBRUN MARC-HENRI; ZUNDEL JEAN-LUC; EFFANTIN GERALDINE; MORIN VALERIE
<P>PROBLEM TO BE SOLVED: To provide a method for using acetohydroxy acid isomeroreductase for treating fungal diseases affecting crops. <P>SOLUTION: The ILV5 gene which encodes ketol-acid reductoisomerase is inactivated by a fungicidal composition containing an effective amount of an inhibitor against Magnaporthe grisea ketol-acid reductoisomerase, Saccharomyces cerevisiae ketol-acid reductoisomerase and/or Neurospora crassa ketol-acid reductoisomerase, for example, dimethylphosphinoyl-2-hydroxyacetate or N-hydroxy-N-isopropyl oxamate. <P>COPYRIGHT: (C)2011,JPO&INPIT

3 4 5 6 7 8 9 10 11 12

IPRDB

热门服务

关于我们

友情链接

联系方式